Open Payments

National Jewish Health

Type
Teaching hospital
Where
Denver, CO
Medicare CCN
060107
Received
$6,158,214 in 548 records, 2025 ($3,998,937 general, $2,159,276 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment115$3,998,937
2025Research payment433$2,159,276

By company

CompanyRecordsAmountYears
AstraZeneca Pharmaceuticals LP16$1,386,4442025
Boehringer Ingelheim Pharmaceuticals, Inc.52$1,017,6812025
Insmed, Inc.26$830,5332025
Novartis Pharmaceuticals Corporation3$505,2302025
Alexion Pharmaceuticals, Inc.34$339,7162025
Genentech, Inc.10$235,3562025
GENZYME CORPORATION25$225,7972025
E.R. Squibb & Sons, L.L.C.3$192,3462025
CSL Behring23$166,9812025
AstraZeneca UK Limited5$163,2972025
United Therapeutics Corporation79$160,4292025
Apellis Pharmaceuticals, Inc.30$149,4632025
VERTEX PHARMACEUTICALS INCORPORATED3$129,9412025
Regeneron Pharmaceuticals, Inc.25$103,3522025
Paratek Pharmaceuticals, Inc.6$100,6862025
Takeda Pharmaceuticals U.S.A., Inc.34$73,7892025
Verona Pharma, Inc.4$62,2102025
Regeneron Healthcare Solutions, Inc.2$50,0002025
Janssen Research & Development, LLC10$49,5852025
Mannkind Corporation2$37,0082025
NS Pharma, Inc.10$28,3582025
Viatris Specialty LLC1$20,0002025
Merck Sharp & Dohme LLC3$19,6582025
ARGENX US, INC.7$17,8602025
Life Technologies Corporation1$15,1402025
Alnylam Pharmaceuticals Inc.1$10,5002025
Sumitomo Pharma Co., Ltd.1$10,0002025
Beckman Coulter, Inc.1$10,0002025
Boehringer Ingelheim International GmbH99$7,2222025
Electromed, Inc.2$7,0002025
Grifols USA, LLC2$5,5002025
Bayer Healthcare Pharmaceuticals Inc.2$5,0002025
Becton, Dickinson and Company19$4,7122025
Baxter Healthcare1$4,0002025
Genentech USA, Inc.1$3,5002025
ABBVIE INC.1$3,5002025
X4 Pharmaceuticals, Inc.1$3,0002025
Incyte Corporation1$2,3352025
Fisher Scientific Company L.L.C.1$1,0212025
QIAGEN, LLC1$562025

By nature of payment

NatureRecordsAmount
Grant17$3,103,297
Research payment433$2,159,276
Compensation for services other than consulting, including serving as faculty or as a speaker at a v42$626,984
Space rental or facility fees (teaching hospital only)19$91,375
Charitable Contribution3$61,500
Gift2$50,000
Royalty or License24$43,352
Consulting Fee3$10,851
Education3$10,500
Debt forgiveness2$1,078

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Merck Sharp & Dohme LLC$4,861Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot2025
2025-12-31Electromed, Inc.$4,000Consulting FeeCash or cash equivalentSMARTVEST Device, HFCWO2025
2025-12-31Takeda Pharmaceuticals U.S.A., Inc.$135Research paymentCash or cash equivalentLONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)2025
2025-12-29Paratek Pharmaceuticals, Inc.$29,673Research paymentCash or cash equivalentNUZYRA Drug, ANTIBIOTIC2025
2025-12-24United Therapeutics Corporation$3,939Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-24United Therapeutics Corporation$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-12-24ARGENX US, INC.$2,291Research paymentCash or cash equivalent2025
2025-12-24United Therapeutics Corporation$886Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-24United Therapeutics Corporation$886Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-12-24United Therapeutics Corporation$770Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-22Boehringer Ingelheim Pharmaceuticals, Inc.$78,986Research paymentCash or cash equivalentOFEV Drug, RESPIRATORYEvaluation of short-term change in quantitative CT as a marker of progressive pulmonary fibrosis2025
2025-12-19Life Technologies Corporation$15,140Royalty or License (19 payments)Cash or cash equivalent2025
2025-12-19Apellis Pharmaceuticals, Inc.$11,900Research paymentCash or cash equivalentStudy to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic 2025
2025-12-19Takeda Pharmaceuticals U.S.A., Inc.$10,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-12-19Apellis Pharmaceuticals, Inc.$5,000Research paymentCash or cash equivalentStudy to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic 2025
2025-12-19Takeda Pharmaceuticals U.S.A., Inc.$2,506Research paymentCash or cash equivalentMULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB2025
2025-12-18Regeneron Pharmaceuticals, Inc.$988Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$530Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$499Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$475Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$399Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$186Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$160Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$140Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$123Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$68Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$65Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$61Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$57Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$54Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-18Regeneron Pharmaceuticals, Inc.$50Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-12-17GENZYME CORPORATION$8,829Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie2025
2025-12-17United Therapeutics Corporation$2,525Research paymentCash or cash equivalentA STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION2025
2025-12-17Boehringer Ingelheim Pharmaceuticals, Inc.$470Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-12-17Boehringer Ingelheim International GmbH$36Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-12-17Boehringer Ingelheim International GmbH$2Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-12-16AstraZeneca Pharmaceuticals LP$33,000Charitable ContributionCash or cash equivalent2025
2025-12-16Boehringer Ingelheim Pharmaceuticals, Inc.$32,301Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-12-15United Therapeutics Corporation$3,124Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2025
2025-12-10ARGENX US, INC.$1,806Research paymentCash or cash equivalent2025
2025-12-10United Therapeutics Corporation$1,732Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-10United Therapeutics Corporation$1,000Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-12-10United Therapeutics Corporation$399Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-12-09AstraZeneca Pharmaceuticals LP$349,337GrantCash or cash equivalent2025
2025-12-09Boehringer Ingelheim Pharmaceuticals, Inc.$185,960GrantCash or cash equivalent2025
2025-12-09AstraZeneca Pharmaceuticals LP$25,000Charitable ContributionCash or cash equivalent2025
2025-12-09Boehringer Ingelheim Pharmaceuticals, Inc.$1,999Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-12-04Takeda Pharmaceuticals U.S.A., Inc.$2,000Research paymentCash or cash equivalentLONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)2025
2025-12-04NS Pharma, Inc.$835Research paymentCash or cash equivalentVILTEPSO Drug, PEDIATRIC NEUROLOGYTrial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis2025
2025-12-03Boehringer Ingelheim Pharmaceuticals, Inc.$13,336Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-12-02Insmed, Inc.$390,810GrantCash or cash equivalent2025
2025-12-01Janssen Research & Development, LLC$6,299Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2025
2025-12-01Boehringer Ingelheim International GmbH$34Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-12-01Boehringer Ingelheim International GmbH$3Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-11-28Apellis Pharmaceuticals, Inc.$1,477Research paymentCash or cash equivalentStudy Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN2025
2025-11-28Apellis Pharmaceuticals, Inc.$725Research paymentCash or cash equivalentA Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)2025
2025-11-26United Therapeutics Corporation$3,172Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-11-26United Therapeutics Corporation$1,819Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-26United Therapeutics Corporation$793Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-26United Therapeutics Corporation$793Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-11-24NS Pharma, Inc.$2,366Research paymentCash or cash equivalentVILTEPSO Drug, PEDIATRIC NEUROLOGYTrial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis2025
2025-11-24NS Pharma, Inc.$1,772Research paymentCash or cash equivalentVILTEPSO Drug, PEDIATRIC NEUROLOGYTrial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis2025
2025-11-20United Therapeutics Corporation$2,949Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2025
2025-11-20Genentech, Inc.$890Research paymentCash or cash equivalentTecentriq Biological, BioOncologyNeoadjuvant NSCLC2025
2025-11-19GENZYME CORPORATION$5,096Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie2025
2025-11-19United Therapeutics Corporation$723Research paymentCash or cash equivalentA STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION2025
2025-11-19Becton, Dickinson and Company$113Royalty or LicenseCash or cash equivalent2025
2025-11-19Becton, Dickinson and Company$68Royalty or LicenseCash or cash equivalent2025
2025-11-19Boehringer Ingelheim International GmbH$43Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-11-19Becton, Dickinson and Company$41Royalty or LicenseCash or cash equivalent2025
2025-11-19Boehringer Ingelheim International GmbH$23Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-11-19Becton, Dickinson and Company$11Royalty or LicenseCash or cash equivalent2025
2025-11-14Genentech USA, Inc.$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentXolair Biological, Immunology2025
2025-11-14Takeda Pharmaceuticals U.S.A., Inc.$2,333Research paymentCash or cash equivalentMULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB2025
2025-11-12United Therapeutics Corporation$4,970Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-12United Therapeutics Corporation$2,612Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-11-12United Therapeutics Corporation$2,612Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-07Genentech, Inc.$82,384Research paymentCash or cash equivalentXolair Biological, ImmunologyEffect of Omalizumab in the Skin of Food Allergy Patients2025
2025-11-07Verona Pharma, Inc.$6,327Research paymentCash or cash equivalentOhtuvayre Drug, Pulmonary/Respiratory DiseasesVerona2025
2025-11-03Boehringer Ingelheim Pharmaceuticals, Inc.$10,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-11-01Takeda Pharmaceuticals U.S.A., Inc.$135Research paymentCash or cash equivalentLONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)2025
2025-11-01Boehringer Ingelheim International GmbH$34Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-11-01Boehringer Ingelheim International GmbH$3Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-30Janssen Research & Development, LLC$399Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2025
2025-10-29Boehringer Ingelheim Pharmaceuticals, Inc.$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-10-29Takeda Pharmaceuticals U.S.A., Inc.$2,333Research paymentCash or cash equivalentMULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB2025
2025-10-28Beckman Coulter, Inc.$10,000Royalty or LicenseCash or cash equivalent2025
2025-10-28Boehringer Ingelheim Pharmaceuticals, Inc.$6,181Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-27Boehringer Ingelheim International GmbH$146Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-27Boehringer Ingelheim International GmbH$99Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-10-27Boehringer Ingelheim International GmbH$73Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-10-27Boehringer Ingelheim International GmbH$23Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-27Boehringer Ingelheim International GmbH$10Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-10-27Boehringer Ingelheim International GmbH$10Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-10-27Boehringer Ingelheim International GmbH$10Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-10-27Boehringer Ingelheim International GmbH$10Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-10-27Boehringer Ingelheim International GmbH$3Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-27Boehringer Ingelheim International GmbH$3Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-27Boehringer Ingelheim International GmbH$0Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-24GENZYME CORPORATION$5,440Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie2025
2025-10-24Apellis Pharmaceuticals, Inc.$450Research paymentCash or cash equivalentA Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)2025
2025-10-23Takeda Pharmaceuticals U.S.A., Inc.$1,000Research paymentCash or cash equivalentMULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB2025
2025-10-22United Therapeutics Corporation$2,839Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-10-16Alexion Pharmaceuticals, Inc.$21,504Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentULTOMIRIS Biological, Rare Disease2025
2025-10-16Alexion Pharmaceuticals, Inc.$2,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentULTOMIRIS Biological, Rare Disease2025
2025-10-16United Therapeutics Corporation$1,077Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2025
2025-10-10Apellis Pharmaceuticals, Inc.$900Research paymentCash or cash equivalentA Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)2025
2025-10-09Alexion Pharmaceuticals, Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentULTOMIRIS Biological, Rare Disease2025
2025-10-09Takeda Pharmaceuticals U.S.A., Inc.$2,333Research paymentCash or cash equivalentMULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB2025
2025-10-09GENZYME CORPORATION$524Research paymentCash or cash equivalentNEXVIAZYME Biological, Genetic DiseaseAn Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ2025
2025-10-08GENZYME CORPORATION$33,679Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie2025
2025-10-08GENZYME CORPORATION$32,462Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyOpen Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S2025
2025-10-08VERTEX PHARMACEUTICALS INCORPORATED$17,645GrantCash or cash equivalent2025
2025-10-08Paratek Pharmaceuticals, Inc.$14,593Research paymentCash or cash equivalentNUZYRA Drug, ANTIBIOTIC2025
2025-10-03Boehringer Ingelheim Pharmaceuticals, Inc.$6,807Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-03Apellis Pharmaceuticals, Inc.$4,000Research paymentCash or cash equivalent2025
2025-10-03GENZYME CORPORATION$300Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie2025
2025-10-02Regeneron Pharmaceuticals, Inc.$34,998Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONPredictors and characteristics of asthma remission in individuals with moderate to severe asthma receiving dupilumab.2025
2025-10-01Boehringer Ingelheim Pharmaceuticals, Inc.$7,300Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-10-01ARGENX US, INC.$1,486Research paymentCash or cash equivalent2025
2025-10-01Boehringer Ingelheim International GmbH$34Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-01Boehringer Ingelheim International GmbH$3Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-09-30E.R. Squibb & Sons, L.L.C.$88Research paymentCash or cash equivalentA Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizum2025
2025-09-25Boehringer Ingelheim Pharmaceuticals, Inc.$14,439Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-09-24Boehringer Ingelheim International GmbH$146Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-09-24Boehringer Ingelheim International GmbH$23Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-09-23Becton, Dickinson and Company$3,000Royalty or LicenseCash or cash equivalent2025
2025-09-22United Therapeutics Corporation$3,364Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2025
2025-09-18Takeda Pharmaceuticals U.S.A., Inc.$2,333Research paymentCash or cash equivalentMULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB2025
2025-09-17Regeneron Pharmaceuticals, Inc.$27,732Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONPredictors and characteristics of asthma remission in individuals with moderate to severe asthma receiving dupilumab.2025
2025-09-17GENZYME CORPORATION$600Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie2025
2025-09-12GENZYME CORPORATION$151Research paymentCash or cash equivalentNEXVIAZYME Biological, Genetic DiseaseAn Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ2025
2025-09-11Alexion Pharmaceuticals, Inc.$8,940Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentULTOMIRIS Biological, Rare Disease2025
2025-09-11Alexion Pharmaceuticals, Inc.$500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentULTOMIRIS Biological, Rare Disease2025
2025-09-11GENZYME CORPORATION$99Research paymentCash or cash equivalentNEXVIAZYME Biological, Genetic DiseaseAn Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ2025
2025-09-10United Therapeutics Corporation$3,000Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-09-10United Therapeutics Corporation$2,639Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-09-10United Therapeutics Corporation$1,819Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-09-10United Therapeutics Corporation$1,578Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-09-10United Therapeutics Corporation$799Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-09-10United Therapeutics Corporation$533Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-09-04Boehringer Ingelheim Pharmaceuticals, Inc.$7,300Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-09-04NS Pharma, Inc.$2,926Research paymentCash or cash equivalentVILTEPSO Drug, PEDIATRIC NEUROLOGYTrial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis2025
2025-09-04Boehringer Ingelheim Pharmaceuticals, Inc.$2,075Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-09-04Boehringer Ingelheim Pharmaceuticals, Inc.$626Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-09-03CSL Behring$3,600Research paymentCash or cash equivalentHizentra Biological, ImmunologyDouble-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immun2025
2025-09-03CSL Behring$3,200Research paymentCash or cash equivalentHizentra Biological, ImmunologyDouble-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immun2025
2025-09-03CSL Behring$500Research paymentCash or cash equivalentHizentra Biological, ImmunologyDouble-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immun2025
2025-09-01Boehringer Ingelheim Pharmaceuticals, Inc.$239,216GrantCash or cash equivalent2025
2025-09-01Boehringer Ingelheim Pharmaceuticals, Inc.$5,000Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-09-01Boehringer Ingelheim Pharmaceuticals, Inc.$1,848Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-09-01Boehringer Ingelheim International GmbH$34Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-09-01Boehringer Ingelheim International GmbH$3Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-08-29Insmed, Inc.$50,000GrantCash or cash equivalent2025
2025-08-29Mannkind Corporation$1,593Research paymentCash or cash equivalentICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION2025
2025-08-29Apellis Pharmaceuticals, Inc.$1,142Research paymentCash or cash equivalentStudy Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN2025
2025-08-29Apellis Pharmaceuticals, Inc.$365Research paymentCash or cash equivalentStudy Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN2025
2025-08-28Grifols USA, LLC$2,000EducationCash or cash equivalentProlastin-C Liquid Biological, Pulmonology2025
2025-08-27Regeneron Healthcare Solutions, Inc.$47,500GrantCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-08-27United Therapeutics Corporation$1,819Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-08-27ARGENX US, INC.$1,380Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolera2025
2025-08-26Boehringer Ingelheim Pharmaceuticals, Inc.$38,850GrantCash or cash equivalent2025
2025-08-26Boehringer Ingelheim International GmbH$255Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-26Becton, Dickinson and Company$159Royalty or LicenseCash or cash equivalent2025
2025-08-26Becton, Dickinson and Company$95Royalty or LicenseCash or cash equivalent2025
2025-08-26Boehringer Ingelheim International GmbH$65Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-26Boehringer Ingelheim International GmbH$59Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-26Boehringer Ingelheim International GmbH$58Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-26Becton, Dickinson and Company$47Royalty or LicenseCash or cash equivalent2025
2025-08-26Becton, Dickinson and Company$38Royalty or LicenseCash or cash equivalent2025
2025-08-26Becton, Dickinson and Company$33Royalty or LicenseCash or cash equivalentHorizon Device, Reagents2025
2025-08-26Boehringer Ingelheim International GmbH$20Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-26Boehringer Ingelheim International GmbH$20Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-26Boehringer Ingelheim International GmbH$20Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-26Boehringer Ingelheim International GmbH$20Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-26Boehringer Ingelheim International GmbH$10Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-21Alexion Pharmaceuticals, Inc.$5,145Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentULTOMIRIS Biological, Rare Disease2025
2025-08-21Takeda Pharmaceuticals U.S.A., Inc.$2,333Research paymentCash or cash equivalentMULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB2025
2025-08-21NS Pharma, Inc.$1,772Research paymentCash or cash equivalentVILTEPSO Drug, PEDIATRIC NEUROLOGYTrial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis2025
2025-08-19Boehringer Ingelheim Pharmaceuticals, Inc.$2,269Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-08-19NS Pharma, Inc.$815Research paymentCash or cash equivalentVILTEPSO Drug, PEDIATRIC NEUROLOGYTrial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis2025
2025-08-19Boehringer Ingelheim Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-08-14Alexion Pharmaceuticals, Inc.$900Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentULTOMIRIS Biological, Rare Disease2025
2025-08-13GENZYME CORPORATION$3,732Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyOpen-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Pediatric Patients With Mod2025
2025-08-13GENZYME CORPORATION$3,732Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyOpen Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S2025
2025-08-13United Therapeutics Corporation$240Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2025
2025-08-12Boehringer Ingelheim Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-08-07Takeda Pharmaceuticals U.S.A., Inc.$2,333Research paymentCash or cash equivalentMULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB2025
2025-08-06ARGENX US, INC.$447Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolera2025
2025-08-01Boehringer Ingelheim Pharmaceuticals, Inc.$4,000Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-08-01Boehringer Ingelheim International GmbH$3,131Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-01Boehringer Ingelheim Pharmaceuticals, Inc.$399Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-08-01Boehringer Ingelheim International GmbH$362Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-01Boehringer Ingelheim International GmbH$238Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYA double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i2025
2025-08-01Boehringer Ingelheim International GmbH$34Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-08-01Boehringer Ingelheim International GmbH$3Research paymentIn-kind items and servicesJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-07-31Regeneron Pharmaceuticals, Inc.$25,000Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-07-31Regeneron Pharmaceuticals, Inc.$2,666Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025
2025-07-31Regeneron Pharmaceuticals, Inc.$2,500Research paymentCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATIONAIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM2025

The latest 200 records of 548.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Denver CountyDenver city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Denver, CO, county Denver County, CO, state Colorado; placed by its city name.

MeasurePlace (city or town)
Denver, CO
County
Denver County, CO
State
Colorado
Population B01003718,877718,8775,862,189
Population, 2020 census P1715,522715,5225,773,714
Median age B0100235.335.337.7
Under 18 B0100118.0%18.0%21.0%
65 and over B0100112.5%12.5%15.6%
Households B11001335,428335,4282,374,218
Foreign born B0500214.5%14.5%9.8%
Median household income B19013$94,718$94,718$95,470
Median family income B19113$124,743$124,743$119,139
Per capita income B19301$64,163$64,163$52,636
Poverty rate B1700111.2%11.2%9.4%
Unemployment rate B230254.9%4.9%4.6%
Civilian labor force B23025447,681447,6813,235,476
Mean commute (minutes) B0801324.924.925.2
Bachelor's degree or higher B1500356.5%56.5%45.7%
Housing units B25001359,581359,5812,589,053
Owner-occupied B2500348.8%48.8%66.2%
Renters B2500351.2%51.2%33.8%
Median home value B25077$616,000$616,000$539,400
Median gross rent B25064$1,831$1,831$1,761
White, not Hispanic B0300254.0%54.0%64.8%
Black B030028.6%8.6%3.8%
Hispanic or Latino B0300228.0%28.0%22.5%
Asian B030023.6%3.6%3.2%
American Indian and Alaska Native B030020.3%0.3%0.4%

Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); Unemployment rate: 3.0% in Sep 2016 to 4.1% in Sep 2026; low 2.4%, high 11.7% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, CO.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.